Actively Recruiting
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Led by Arrowhead Pharmaceuticals · Updated on 2026-01-09
78
Participants Needed
1
Research Sites
79 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
CONDITIONS
Official Title
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to follow diet counseling as per Investigator judgment based on local standard of care
- Specific fasting triglycerides, low-density lipoprotein cholesterol, and non-high density lipoprotein cholesterol levels at screening
- Participants of childbearing potential must agree to use highly effective contraception plus condom during the study and for at least 90 days after the study or last study drug dose
- Participants must not donate sperm or eggs during the study and for at least 90 days after the study or last study drug dose
You will not qualify if you...
- Current use or use within last 365 days or within 5 half-lives before Day 1 of any hepatocyte-targeted siRNA
- Current use or use within last 90 days or within 5 half-lives before Day 1 of any antisense oligonucleotide therapy
- Current use or use within last 60 days from Day 1 of any PCSK9 inhibitor monoclonal antibodies (eg, evolocumab or alirocumab)
- Uncontrolled hypertension
- History of bleeding diathesis or coagulopathy
- Current diagnosis of nephrotic syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site 1
Christchurch, New Zealand, 8011
Actively Recruiting
Research Team
M
Medical Monitor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here